Refine by
Pharmaceutics Articles & Analysis: This-Year
1 articles found
Outlook In vivo CAR-T remains an emerging modality, but recent clinical progress, academic validation, and major pharmaceutical investment suggest strong long-term potential. As delivery technologies mature, the integration of mRNA engineering, targeted lipid nanoparticles, and functional PEG-lipids is expected to play a defining role in expanding the reach of cell ...